Journal: Journal of Translational Medicine

Article Title: Combined IL-21 and Low-Dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model

doi: 10.1186/1479-5876-4-24

Figure Lengend Snippet: Tumor-specific protective immunity in long-term survivor mice. IL-21 + IL-2 treated mice that survived disease free for 150 days were rechallenged with B16F10 (5 × 10 5 ) or 3LL(5 × 10 4 ) tumor cells. All 3LL challenged mice (4/4) exhibited mean tumor growth to ≥ 200 mm 2 by day 32; all B16F10 challenged mice (5/5) were protected. Naïve mice challenged with the same B16F10 (5/5) or 3LL (5/5) tumor cells had rapid mean tumor growth to ≥ 200 mm 2 by day 25.

Article Snippet: The B16 F10 melanoma and 3LL (Lewis Lung) cell lines were obtained from ATCC.

Techniques:

Journal: PLoS ONE

Article Title: An In Situ Autologous Tumor Vaccination with Combined Radiation Therapy and TLR9 Agonist Therapy

doi: 10.1371/journal.pone.0038111

Figure Lengend Snippet: The immunomodulatory effect of TLR agonist and RT was tested in both short term (A) and long term animal studies (B). Experiments were carried out on both C57BL/6 wildtype and cogenic B cell deficient mice. Mice were inoculated with 1×10 5 3LL cells on day 0 and were divided into 5 groups (n = 15/group for wildtype and n = 10/group for B cell deficient mice) that received either no treatment, 20 Gy RT of the primary tumor on day 14 post-tumor inoculation, only control oligo, only TLR9 agonist, or the combination of tumor RT, followed immediately by TLR9 agonist injection on day 14. For short term studies, 25 wildtype or B cell deficient mice were sacrificed on day 15 and splenocytes were harvested for flow cytometry. For long term studies, 75 wildtype and 50 B cell deficient mice were used. TLR9 agonist was injected subcutaneously, twice a week for three weeks (from day 14 to 35). The tumor volume was measured at 1–3-day intervals with a vernier caliper. Of the 75 wildtype mice, 40 mice were sacrificed on day 35 for immunological studies and the remaining 35 mice were used for survival studies. For B cell deficient mice, all of them were sacrificed on day 35 and were used for immunological studies.

Article Snippet: Lewis lung carcinoma (3LL) cells (American Type Culture Collection, Manassas, VA) was propagated in high glucose DMEM supplemented with 10% FBS, sodium pyruvate, non-essential amino acids and 100 U/ml of penicillin and streptomycin (Invitrogen, Carlsbad, CA).

Techniques: Control, Injection, Flow Cytometry

Journal: PLoS ONE

Article Title: An In Situ Autologous Tumor Vaccination with Combined Radiation Therapy and TLR9 Agonist Therapy

doi: 10.1371/journal.pone.0038111

Figure Lengend Snippet: TLR9 agonist induces the proliferation of TLR9-expression splenocytes in mice bearing an ectopic 3LL footpad tumor.

Article Snippet: Lewis lung carcinoma (3LL) cells (American Type Culture Collection, Manassas, VA) was propagated in high glucose DMEM supplemented with 10% FBS, sodium pyruvate, non-essential amino acids and 100 U/ml of penicillin and streptomycin (Invitrogen, Carlsbad, CA).

Techniques: Control

Journal: PLoS ONE

Article Title: An In Situ Autologous Tumor Vaccination with Combined Radiation Therapy and TLR9 Agonist Therapy

doi: 10.1371/journal.pone.0038111

Figure Lengend Snippet: C57BL/6 mice bearing 3LL tumor were divided into 5 groups receiving either PBS, control oligo, TLR9 agonist, RT (20 Gy) or RT+TLR9 agonist. Splenocytes and sera were harvested 24 hours after treatment. The activation of CD8+ T cells, B cells, pDCs and NKDCs was analyzed by flow cytometry (A) and the release of IFN-γ and IL-10 was analyzed by ELISA (B).

Article Snippet: Lewis lung carcinoma (3LL) cells (American Type Culture Collection, Manassas, VA) was propagated in high glucose DMEM supplemented with 10% FBS, sodium pyruvate, non-essential amino acids and 100 U/ml of penicillin and streptomycin (Invitrogen, Carlsbad, CA).

Techniques: Control, Activation Assay, Flow Cytometry, Enzyme-linked Immunosorbent Assay

Journal: PLoS ONE

Article Title: An In Situ Autologous Tumor Vaccination with Combined Radiation Therapy and TLR9 Agonist Therapy

doi: 10.1371/journal.pone.0038111

Figure Lengend Snippet: Sera from tumor bearing mice treated with either PBS, control oligo, TLR9 agonist, RT (20 Gy) or combined RT and TLR9 agonist were analyzed for the presence of tumor specific antibodies by indirect ELISA coated with total 3LL tumor lysate (A). The total IgG titer was evaluated by an Easy-Titer Mouse IgG Assay Kit (B) and the infiltration of IgG antibody was visualized by confocal microscope after stained with FITC conjugated anti-mouse IgG (C).

Article Snippet: Lewis lung carcinoma (3LL) cells (American Type Culture Collection, Manassas, VA) was propagated in high glucose DMEM supplemented with 10% FBS, sodium pyruvate, non-essential amino acids and 100 U/ml of penicillin and streptomycin (Invitrogen, Carlsbad, CA).

Techniques: Control, Indirect ELISA, Microscopy, Staining

Journal: PLoS ONE

Article Title: An In Situ Autologous Tumor Vaccination with Combined Radiation Therapy and TLR9 Agonist Therapy

doi: 10.1371/journal.pone.0038111

Figure Lengend Snippet: Wild type (C57BL/6) or congenic B cell deficient mice (Igh-6 tm1Cgn ) bearing 3LL tumors were divided into 5 groups receiving either PBS, control oligo, TLR9 agonist, RT (20 Gy) or RT+TLR9 agonist. Tumor growth curves were generated by measuring three orthogonal tumor diameters at 1–3-day intervals with a vernier caliper.

Article Snippet: Lewis lung carcinoma (3LL) cells (American Type Culture Collection, Manassas, VA) was propagated in high glucose DMEM supplemented with 10% FBS, sodium pyruvate, non-essential amino acids and 100 U/ml of penicillin and streptomycin (Invitrogen, Carlsbad, CA).

Techniques: Control, Generated